imo, the options at $6.15 motivate the directors to keep the stock above and beyond six bucks. A week ago, this would have seemed like a reasonable carrot. The number of shares granted seems a bit generous to me, but if it helps to get the most out of Leronlimab's potential its probably a good thing.